Status:
TERMINATED
Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome
Lead Sponsor:
Centre Hospitalier Henri Duffaut - Avignon
Conditions:
COVID-19 Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In the current COVID-19 pandemic, many patients have an acute respiratory distress syndrome (ARDS). Among mechanisms related to COVID-19 acute respiratory distress syndrome, cytokine storm and secreti...
Eligibility Criteria
Inclusion
- Age\>18 years
- Patients with COVID-19 (positive COVID PCR)
- Use of intubation for mechanical ventilation
Exclusion
- Use of Extracorporeal Membrane Oxygenation
- Treatment with Tocilizumab (anti-Il6)
- Pregnant woman
- Patients under protective administration or deprived of liberty
Key Trial Info
Start Date :
August 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05330845
Start Date
August 5 2021
End Date
December 31 2022
Last Update
May 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Henri Duffaut
Avignon, Vaucluse, France, 84000